Tower Cold Chain, a provider of passive temperature-controlled containers, introduced the KTEvolution 12, offering a new standard in small parcel solutions for pharmaceutical products, with a unique plate design.
 
The KTEvolution 12 integrates Tower’s existing phase-change materials (PCM) or dry ice into a new pyramid-shaped configuration. This plate system is designed to guarantee improved internal temperature consistency, even when the container is placed on its side.
 
Purpose-built for last-mile delivery, laboratory distribution, and clinical trials, the KTEvolution 12 is designed to provide the safe transport of thermally sensitive products requiring internal temperatures ranging from <-60°C to above +20°C with maximum product protection. 
 
Tailored specifically for the transportation needs of life science products, including high-value commercial products, cell and gene therapies, as well as research and development shipments, the container provides security throughout the pharmaceutical supply chain.
 
With an internal payload up to 12 litres, it maintains thermal control for over 96 hours without the use of external power or human intervention during transit, meaning products can be reliably shipped both domestically and internationally in a parcel-sized box.
 
“The KTEvolution 12’s innovative design not only ensures superior temperature consistency but also prioritizes durability and sustainability,” said Martin Hawes, Global Head of Product Development at Tower Cold Chain. “With a 30% increase in thermal performance compared to semi-reusable solutions, our newest container exemplifies Tower’s commitment to pushing the boundaries of sustainable cold chain technology.”